Dimethyl fumarate — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Dimethyl fumarate appears in hypotheses across 6 disease domains: ALS, Epilepsy, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: Nrf2, NRF2, NQO1.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Dimethyl fumarate

ALS 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
NRF2	antioxidant defense	0.369	High	reproduces known	none

Epilepsy 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
NQO1	brain malignancy	0.208	Mid	novel signal	completed
NQO1	abnormal neurotransmitter release	0.208	Mid	novel signal	none

Inflammatory bowel disease 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
Nrf2 pathway	tau clearance	0.289	High	novel signal	none

Pancreatic cancer 5

Mediator	Outcome	Score	Tier	Lit. status	Trial
NRF2	chemoresistance	0.409	High	partial evidence	none
Nrf2	chemoresistance	0.409	High	partial evidence	none
Nrf2	poor prognosis	0.369	High	reproduces known	none
NRF2	poor prognosis	0.369	High	reproduces known	none
NQO1	pancreatic cancer	0.208	Mid	partial evidence	none

Rheumatoid arthritis 5

Mediator	Outcome	Score	Tier	Lit. status	Trial
Nrf2	rheumatoid arthritis	0.409	High	reproduces known	completed
Nrf2	efficacy of synthetic anti-rheumatic drugs	0.369	High	novel signal	none
Nrf2	toxicity of conventional anti-rheumatic therapies	0.369	High	novel signal	none
Nrf2	drug efflux	0.369	High	novel signal	none
Nrf2	interstitial lung disease	0.369	High	novel signal	none

Type 2 diabetes 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
Nrf2	type 1 diabetes	0.369	High	reproduces known	active

← All drugs